papaverine has been researched along with camostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bojkova, D; Ciesek, S; Cinatl, J; Claussen, C; Ellinger, B; Geisslinger, G; Gribbon, P; Keminer, O; Kuzikov, M; Reinshagen, J; Westhaus, S; Wolf, M; Zaliani, A | 1 |
2 other study(ies) available for papaverine and camostat
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection.
Topics: Antiviral Agents; Benzamidines; Caco-2 Cells; Cetylpyridinium; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Esters; Guanidines; Humans; Lopinavir; Mefloquine; Papaverine; SARS-CoV-2 | 2021 |